Vice President, Head Of Oncology Research
Current
Sep 2023 - Present
AeroLeads people directory · profile
Robert W. Wilkinson, Ph.D. Email & Phone Number
Vice President, Head of Oncology Research
at
Immunocore
LinkedIn matched
✓ Verified Jul 2026
3 data sources
Profile completeness 86%
Current company
Role
Vice President, Head of Oncology Research
Location
Greater Cambridge Area, United Kingdom
Who is Robert W. Wilkinson, Ph.D.? Overview
A concise factual answer block for searchers comparing this professional profile.
Quick answer
Robert W. Wilkinson, Ph.D. is listed as Vice President, Head of Oncology Research at Immunocore, based in Greater Cambridge Area, United Kingdom. AeroLeads shows a matched LinkedIn profile for Robert W. Wilkinson, Ph.D..
Robert W. Wilkinson, Ph.D. previously worked as Executive Director, Global Head of NextGen Immuno-Oncology (IO) at Astrazeneca and Senior Director, Head of Cambridge Oncology Research at Astrazeneca. Robert W. Wilkinson, Ph.D. holds Doctor Of Philosophy - Phd, Experimental Immunology from University Of Birmingham.
Company email context
Email format at Immunocore
This section adds company-level context without repeating Robert W. Wilkinson, Ph.D.'s masked contact details.
Immunocore
Review company-level records connected to Robert W. Wilkinson, Ph.D. before choosing the right outreach path.
Profile bio
About Robert W. Wilkinson, Ph.D.
An experienced, inspirational oncology drug hunter with deep understanding of small molecule and biologics drug discovery. Helped to bring many new drugs into clinical trials, including a key contributor to the nomination of 13 candidate drugs (CDs) and >10 investigational new drugs (INDs), and 2 launched drugs, Imfinzi® (PD-L1) and Imjudo® (CTLA-4).An authentic leader with a passion for building and leading high-functioning teams/organisations doing groundbreaking cancer research and drug discovery. Strong communicator with a proven ability to influence broadly at all levels, driving innovation and raising scientific quality whilst promoting a culture of trust and mutual integrity.A pioneer in Immuno-oncology (IO) drug discovery, at AstraZeneca/MedImmune proposed PD-L1 as a T cell checkpoint target and devised the drug discovery plan. Since the first approval in 2017, more than 150,000 patients have been treated with Imfinzi®. A core contributor of multiple other IO discovery programs, including Volrustomig (formerly MEDI5752) a bispecific antibody targeting PD1/CTLA-4, currently in Phase III. Recently, conceived AstraZeneca's NextGen IO scientific vision, led the global NextGen IO unit and translated its strategy into action, establishing a sustainable NextGen discovery pipeline.A track record of identifying and implementing novel drug platforms, spanning small molecules (antineoplastic kinase inhibitors, TLR agonists), fusion protein, mono- and bispecific antibodies, antibody-drug conjugates (ADCs), mRNA, and oncolytic virotherapy.An expert scientist in cancer biology, immunology, and drug discovery/translation having presented at national and international scientific meetings and been a co-author on over 85 peer-reviewed publications.
Current workplace
Robert W. Wilkinson, Ph.D.'s current company
Company context helps verify the profile and gives searchers a useful next step.
9 roles · 30 years
Robert W. Wilkinson, Ph.D. work experience
A career timeline built from the work history available for this profile.
Executive Director, Global Head Of Nextgen Immuno-Oncology (Io)
At AstraZeneca I conceived the NextGen IO scientific vision and led a global cross-functional team across UK and US sites. My role involved translating the strategy into tangible action plans. I assumed the responsibility of overseeing and managing the NextGen IO portfolio, ensuring seamless progression of projects from research and target selection through to IND. In under 18 months I established a sustainable NextGen IO pipeline encompassing myeloid and T cell small molecule and biologics approaches.
May 2021 - Aug 2023
Senior Director, Head Of Cambridge Oncology Research
May 2019 - May 2021
Director, Head Of Cambridge Oncology Research
At Medimmune (a fully owned AstraZeneca group) led the cancer biologics discovery department in Cambridge. Directed projects from target discovery/proof-of-concept to IND filing and translational support, with a ‘commitment to excellence’. Helped to build a strong preclinical and clinical portfolio of novel immuno-oncology and antibody-drug conjugate therapeutics. Developed innovation state-of-the-art capabilities in drug discovery and complex preclinical models of cancer. Managed a talented, multi-disciplined group of scientists and led or participated in numerous industry (e.g., Moderna, Immunocore, 3M) and industry-academia (e.g., AZ-CRUK Antibody Alliance Lab) collaborations, and contribute to overall oncology strategy.
Jan 2012 - May 2019
Principal Scientist
At AstraZeneca formed a translational in vivo pharmacology team and delivered datasets to support the preclinical and clinical oncology small molecule pipeline. Worked across multiple areas of cancer biology, including cell cycle, growth factors, vascular modulation, invasion, and immunotherapy. Presented scientific findings at international conferences and co-authored over 30 peer-reviewed papers between 2006 and 2013, on small molecule kinase inhibitors such as Caprelsa®, Iressa®, and Koselugo®.Established AZ’s immunotherapy interests and pipeline, through biologics target proposals in collaboration with Abgenix/Amgen; and was the AZ Lead Biologist on the small molecule TLR7 agonist program in collaboration with Sumitomo Pharma. Led an in vivo pharmacology team which contributed to the discovery of 3 CD nominations and two INDs for Aurora kinase B (Barasertib/AZD1152 and AZD3646) and CDK2 (AZD5438) inhibitors.
Nov 2008 - Jan 2012
Team Leader, Head Of Discovery Medicine In Vivo (Uk)
Apr 2006 - Nov 2008
Team Leader
Apr 2004 - Apr 2006
Associate Team Leader
Jun 2001 - Apr 2004
Team Leader/Post Doc
1997 - 2001
~4 yrs
2 education records
Robert W. Wilkinson, Ph.D. education
Doctor Of Philosophy - Phd, Experimental Immunology
University Of Birmingham
Bachelor Of Science - Bsc (Hons), Human And Applied Biology
Aston University
FAQ
Frequently asked questions about Robert W. Wilkinson, Ph.D.
Quick answers generated from the profile data available on this page.
What company does Robert W. Wilkinson, Ph.D. work for?
Robert W. Wilkinson, Ph.D. works for Immunocore.
What is Robert W. Wilkinson, Ph.D.'s role at Immunocore?
Robert W. Wilkinson, Ph.D. is listed as Vice President, Head of Oncology Research at Immunocore.
Where is Robert W. Wilkinson, Ph.D. based?
Robert W. Wilkinson, Ph.D. is based in Greater Cambridge Area, United Kingdom while working with Immunocore.
What companies has Robert W. Wilkinson, Ph.D. worked for?
Robert W. Wilkinson, Ph.D. has worked for Immunocore, Astrazeneca, Medimmune, and Cancer Research Technology.
How can I contact Robert W. Wilkinson, Ph.D.?
You can use AeroLeads to view verified contact signals for Robert W. Wilkinson, Ph.D. at Immunocore, including work email, phone, and LinkedIn data when available.
What schools did Robert W. Wilkinson, Ph.D. attend?
Robert W. Wilkinson, Ph.D. holds Doctor Of Philosophy - Phd, Experimental Immunology from University Of Birmingham.
Find 750M verified contacts
Search by job title, company, industry, location, and seniority. Export verified B2B contact data when you need it.
Start free trial